The molecules we develop at IMD-Pharma have the potential to become « first-in-class » drugs for the treatment of chronic inflammatory diseases. The therapeutic efficacy of our leads has been demonstrated in several clinically recognized animal models of common CIDs, like rheumatoid arthritis (RA), psoriasis and multiple sclerosis (MS).

Drug candidates developed at IMD-Pharma are orally bioavailable, and, when required, specific formulations have been developed in collaboration with academic partners to increase skin penetration or to access the central nervous system.

Our lead investigational drug IMD-026 is currently in late non-clinical development for the treatment of RA. It is an improved version of IMD-006, which has the potential to inhibit bone resorption and cartilage destruction, turning blocked and painful joints into functional ones, while addressing systemic inflammation in a non-immunosuppressive manner.